April 30th 2024
A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia.
The reality of a sickle cell disease cure brings fear, optimism, and questions to patients’ lives; veterans who are in suicidal crisis can receive free emergency care at any Department of Veterans Affairs or private facility; Pfizer to increase access to progressive treatments through sale of drugs at non-profit prices to poor countries.
Read More
Analysis of Beti-Cel for Severe β-Thalassemia Shows Extensive, Long-term Patient Improvement
December 20th 2022A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell administration and marked improvements in patient-reported outcomes, including the ability to work and be physically active.
Read More
Some Patients With CAD Experience Sustained Remission After Sutimlimab Discontinuation
November 18th 2022A research letter published in Blood Advances details the first clinical evidence of sustained hematologic remission for cold agglutinin disease (CAD) after sutimlimab treatment discontinuation.
Read More
Study Highlights Value of PROs in Children With Sickle Cell Disease During Acute Pain Episodes
November 14th 2022Sufficiently powered studies are necessary to investigate associations between clinical measures and patient-reported outcomes (PROs) in children with sickle cell disease experiencing acute pain episodes, according to a recent study.
Read More
Report Suggests Best Practices for Care of Pediatric Sickle Cell Disease
November 12th 2022A panel of specialists proposed 26 essential elements for comprehensive pediatric sickle cell disease care, laying groundwork for standardized guidelines and the establishment of accredited care centers in the future.
Read More
Review Highlights Advances in SCD Treatment, Potential Targets for Novel Agents
September 17th 2022The review discusses hydroxyurea and 3 additional drugs approved by the FDA—L-glutamine, crizanlizumab, and voxelotor—as well as agents currently being investigated to treat sickle cell disease (SCD).
Read More
Hemoglobin Improvement Correlates With Better HRQOL in Paroxysmal Nocturnal Hemoglobinuria
September 1st 2022Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal nocturnal hemoglobinuria, for an overall bettering of health-related quality of life (HRQOL).
Read More
Young Adults With SCD Show Better Hydroxyurea Adherence Than Children, Adolescents
August 6th 2022With adherence estimated at less than 50% in children, adolescents, and young adults, a recent study stresses the importance of treatment adherence for patients with sickle cell disease receiving hydroxyurea and the benefit for those who do.
Read More
Heavy/Light Chain Assay Useful Marker in Cold Agglutinin Disease, Study Suggests
August 1st 2022Current standard modalities for detecting and quantifying monoclonal immunoglobin in patients with cold agglutinin disease lack adequate sensitivity. Heavy chain/light chain assay may be more effective.
Read More
Study Identifies Risk Factors for Thrombosis in Patients With AIHA
July 29th 2022This retrospective study and prospective follow-up provide insight into predictors of thrombotic episodes in patients with autoimmune hemolytic anemia (AIHA) and indicators that anticoagulant prophylaxis may be beneficial to certain patients.
Read More